Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Aquestive Therapeutics Inc before investing.

In this article, we go over a few key elements for understanding Aquestive Therapeutics Inc’s stock price such as:

• Aquestive Therapeutics Inc’s current stock price and volume
• Why Aquestive Therapeutics Inc’s stock price changed recently
• Upgrades and downgrades for AQST from analysts
• AQST’s stock price momentum as measured by its relative strength

About Aquestive Therapeutics Inc (AQST)

Before we jump into Aquestive Therapeutics Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company’s Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.

Want to learn more about Aquestive Therapeutics Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc’s Stock Price as of Market Close

As of September 27, 2024, 3:59 PM, CST, Aquestive Therapeutics Inc’s stock price was $4.72.

Aquestive Therapeutics Inc is down 5.6% from its previous closing price of $5.00.

During the last market session, Aquestive Therapeutics Inc’s stock traded between $4.89 and $5.07. Currently, there are 90.91 million shares of Aquestive Therapeutics Inc stock available for purchase.

Unfortunately, Aquestive Therapeutics Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Aquestive Therapeutics Inc Stock Price History

Aquestive Therapeutics Inc’s (AQST) price is currently up 4.19% so far this month.

During the month of September, Aquestive Therapeutics Inc’s stock price has reached a high of $5.29 and a low of $4.10.

Over the last year, Aquestive Therapeutics Inc has hit prices as high as $6.23 and as low as $1.25. Year to date, Aquestive Therapeutics Inc’s stock is up 423.28%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Aquestive Therapeutics Inc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 26, 2024, there were 2 analysts who downgraded Aquestive Therapeutics Inc’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Aquestive Therapeutics Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Aquestive Therapeutics Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Aquestive Therapeutics Inc (AQST) by visiting AAII Stock Evaluator.

Relative Price Strength of Aquestive Therapeutics Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 26, 2024, Aquestive Therapeutics Inc has a weighted four-quarter relative price strength of 47.16%, which translates to a Momentum Score of 98 and is considered to be Very Strong.

Want to learn more about how Aquestive Therapeutics Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Aquestive Therapeutics Inc Stock Price: Bottom Line

As of September 27, 2024, Aquestive Therapeutics Inc’s stock price is $4.72, which is down 5.6% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Aquestive Therapeutics Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.